According to CONMED's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.73184. At the end of 2023 the company had a P/S ratio of 2.71.
Year | P/S ratio | Change |
---|---|---|
2023 | 2.71 | 4.68% |
2022 | 2.58 | -37% |
2021 | 4.10 | 10.45% |
2020 | 3.71 | 11.61% |
2019 | 3.33 | 58.4% |
2018 | 2.10 | 17.52% |
2017 | 1.79 | 11.07% |
2016 | 1.61 | -5.16% |
2015 | 1.70 | 1.17% |
2014 | 1.68 | 8.3% |
2013 | 1.55 | 49.84% |
2012 | 1.03 | 4.59% |
2011 | 0.9884 | -5.42% |
2010 | 1.05 | 9.25% |
2009 | 0.9566 | 2.19% |
2008 | 0.9361 | -1.75% |
2007 | 0.9528 | -4.75% |
2006 | 1.00 | -7.43% |
2005 | 1.08 | -26.74% |
2004 | 1.47 | 5.86% |
2003 | 1.39 | 12% |
2002 | 1.24 | 5.93% |
2001 | 1.17 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 3.85 | 122.18% | ๐บ๐ธ USA |
Medtronic MDT | 3.30 | 90.68% | ๐ฎ๐ช Ireland |
Boston Scientific BSX | 7.53 | 334.57% | ๐บ๐ธ USA |
Stryker Corporation SYK | 6.25 | 261.03% | ๐บ๐ธ USA |
Teleflex TFX | 3.34 | 93.08% | ๐บ๐ธ USA |
Integra LifeSciences IART | 1.50 | -13.50% | ๐บ๐ธ USA |
Smith & Nephew
SNN | 2.33 | 34.33% | ๐ฌ๐ง UK |